Steven K. Budd
Steven is a twenty-five year veteran of the pharmaceutical industry with a wide
range of experience in sales, marketing and medical communications. He has been
involved in the outsourced sales industry since its formative years and is a respected
expert on US Healthcare outsourcing trends. Prior to joining IMC he spent 11 years
at PDI, serving as President since 2000. At PDI he helped vault the company to a
leadership position in providing sales and marketing services to the bio-pharmaceutical
industry, at its peak achieving revenues in excess of $400 million with four thousand
employees and a market valuation of over $1 billion.
Before joining PDI, Steve held
senior level positions at PDN (now the Professional Sales Division of Publicis)
and Innovex, Inc. He began his career as a pharmaceutical sales rep in 1980 and
held mid-to senior-level sales management positions before moving over to the service
side of the industry in 1990. Mr. Budd received a B.A. in History and Education
from Susquehanna in 1978.
Carole Gins, MBA, PMP
Carole Gins joined IMC in 2011 as President. Formerly, as General Manager of IC Axon, Carole was responsible for
overseeing the smooth functioning of the entire company, as well as building its success by increasing revenue, sales and profitability.
To fulfill her role managing a Canadian-based company that serviced a US-based clientele, Carole performed a multitude of tasks.
Her responsibilities included overseeing the Directors of Operations and Content, managing Canadian-based production teams with
a US-based sales team, while regularly working collaboratively with these teams to create and implement innovative solutions.
Carole also actively managed client expectations, ensuring consistent solution implementation and played a key leadership role
in handling challenging project issues.
Before joining IC Axon in 2005, Carole Gins managed complex eLearning applications and web-based HR systems from inception to completion.
She has also served as Web Production Manager, managing development of websites and multimedia CD-ROMs. Carole has significant expertise
in training, project management, and processes re-engineering. Her focus lies primarily in the pharmaceutical and food industries, as well
as communication and marketing services.
Carole holds a degree in Applied Sciences, a degree in multimedia techniques, a Masters in international business, is a certified Project
Management Professional, and holds an executive MBA from McGill-HEC Montreal.
Ted Lundberg
Ted Lundberg joined Ferrer Freeman & Company, LLC in 2000. Prior to FFC, he was a Financial Analyst at Donaldson, Lufkin & Jenrette from 1998 to 2000 with responsibilities in Health Care Investment Banking. Prior to joining DLJ, Mr. Lundberg worked for Cowen & Co. He is a member of the Board of Directors of Aerocare Holdings, Inc., Genova Diagnostics, Inc., Informed Medical Communications, Inc., OrthoRx, Inc. and Webmedx, Inc. He is also an observer of the Board of AgaMatrix, Inc. and K2M, Inc. He holds a B.A. degree from Princeton University.
Brian Morfitt
Mr. Morfitt joined Frazier Healthcare in 2003 as an Associate, became a Senior Associate in 2005, a Vice President in 2007 and a Principal in 2009. Mr. Morfitt assists with the development and review of growth equity investment opportunities and has played significant roles with the firm’s investments in Trident USA Health Services, CHG Healthcare, Pentech Health, Priority Solutions, Bravo Health and Informed Medical Communications.
Prior to joining Frazier Healthcare, Mr. Morfitt was an associate at Summit Partners, a later stage venture capital and private equity firm. While at Summit, he focused on identifying and evaluating middle market growth equity investment opportunities in the healthcare, technology and industrial growth sectors. Mr. Morfitt holds a B.S., Phi Beta Kappa, and an M.S. in Management Science and Engineering from Stanford University.
Brook Lenfest - Brooks Capital Group
Larry Senour
Larry Senour has over 20 years of healthcare experience, including the last 13 years
with Merck & Co., spanning various consulting, business development, licensing and corporate development roles.
He currently serves as Executive Director, Corporate Development, and is responsible for mergers, acquisitions,
joint ventures and strategic alliances. Larry is also responsible for Merck Capital Ventures (MCV), which invests
in emerging businesses with technologies in areas related to the discovery, development and commercialization of
pharmaceuticals and related healthcare services. In addition to IMC, Larry serves on the Board of Directors for
HTG Molecular, and in a Board observer role for several other MCV companies.
Prior to joining Merck, Larry served as Manager at Deloitte Consulting and Regional Manager with Healthcare Services Group.
Larry holds an undergraduate degree from Pennsylvania State University and a M.B.A. from the University of Michigan.
Charles T. Saldarini
Charles T. Saldarini is a successful, innovative entrepreneur
credited with a leading role in the development of one of the healthcare service
industry's leading markets?contract sales, approximately valued at $900 M?and one
of its most respected service companies, PDI, a major player in the market for outsourced
sales and marketing solutions sold to the biopharmaceutical industry. During his
18 year tenure with PDI, he led the company's development from a concept stage through
to its maturity as a publicly traded company with annual revenues of approximately
$365M. He retired from PDI in October, 2005.